<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="df4fa83e-494c-4091-8d34-9328fd030ccd"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES.<br/>
      <br/>
      <content styleCode="bold">DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE (mixed-salts of a single-entity amphetamine product) extended-release capsules, for oral use, CII<br/>
Initial U.S. Approval: 2001</content>
   </title>
   <effectiveTime value="20241227"/>
   <setId root="5e84ef60-3050-40d9-9f14-66b85d289e17"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="022629579" root="1.3.6.1.4.1.519.1"/>
            <name>Teva Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ba245ff1-9e1a-4712-826e-f0c37b089935"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241227"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3683" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.125"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3DYK7UYZ62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (10 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="99Q3C7L77T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="05JZI7B19X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3683-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231010"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210876" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231010"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="orange" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A012;A012</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3684" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6.250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6.250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6.250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6.250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3DYK7UYZ62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (10 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="99Q3C7L77T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="05JZI7B19X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3684-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231010"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210876" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231010"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="green" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A025;A025</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3685" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="9.375"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="9.375"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="9.375"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="9.375"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3DYK7UYZ62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (10 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="99Q3C7L77T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="05JZI7B19X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3685-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231010"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210876" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231010"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="blue" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>blue-green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A038;A038</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3686" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G83415V073" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SACCHARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O1ZPV620O4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE ASPARTATE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JJ768O327N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROAMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TZ47U051FI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROAMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12.500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6DPV8NK46S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMPHETAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CK833KGX7E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMPHETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3DYK7UYZ62" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE (10 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="99Q3C7L77T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLY(METHYL ACRYLATE-CO-METHYL METHACRYLATE-CO-METHACRYLIC ACID 7:3:1; 280000 MW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3686-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20231010"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210876" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231010"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" displayName="blue" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A049;A049</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_acb365b0-6d66-49b7-bec7-c3b1107abdb9">
               <id root="6167bd43-539f-4f30-b730-03a696ba9a75"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: ABUSE, MISUSE, AND ADDICTION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, assess each patients risk for abuse, </content>
                     <content styleCode="bold">misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment, reassess each patients risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#LINK_803928bf-e36e-434d-a9d8-35220fbb9f45">5.1</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#LINK_a55fd202-f540-43f4-97df-636d83602420">9.2</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: ABUSE, MISUSE, AND ADDICTION</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, can result in overdose and death (<linkHtml href="#LINK_803928bf-e36e-434d-a9d8-35220fbb9f45">5.1</linkHtml>,<linkHtml href="#LINK_a55fd202-f540-43f4-97df-636d83602420">9.2</linkHtml>,<linkHtml href="#LINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">10</linkHtml>):</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, assess each patients risk for abuse, misuse, and addiction.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Throughout treatment, reassess each patients risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_170ada83-8659-451c-a5c7-c27d5e72e00d">
               <id root="8dd286c6-f46c-4a8d-ac55-04ed2621c103"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_05a592ef-2f31-471f-bb5c-1adc6415ed1f">14</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>:</paragraph>
                  <paragraph>Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose, and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9eaee862-6b45-4124-b737-68f869e0d1a1">8.4</linkHtml>)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older. (<linkHtml href="#LINK_170ada83-8659-451c-a5c7-c27d5e72e00d">1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>:</paragraph>
                        <paragraph>Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite. (<linkHtml href="#LINK_9eaee862-6b45-4124-b737-68f869e0d1a1">8.4)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ffd58ccb-19a9-4410-8e9a-94fb0a2c8df8">
               <id root="c2198855-b132-4ef2-8d33-a42980e2ba18"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules should be administeredonce daily upon awakening.</item>
                        </list>
                        <table>
                           <col width="20%"/>
                           <col width="26%"/>
                           <col width="19%"/>
                           <col width="35%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Recommended Starting Dose</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Titration Schedule</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Maximum Daily Dose</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Adults</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12.5 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12.5 mg weekly</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>50 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pediatrics (13 to 17)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12.5 mg</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12.5 mg weekly</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>25 mg</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered" styleCode="Disk">
                           <item>In adult patients with severe renal impairment the maximum dose should not exceed 25 mg daily. Use in adult patients with ESRD is not recommended. (<linkHtml href="#LINK_ecc6b955-cc2a-42ca-a5d9-572b3ed9e223">2.6</linkHtml>, <linkHtml href="#LINK_fd505c6e-366b-45b0-8dd1-619bda0da840">8.6</linkHtml>) </item>
                           <item>The maximum dose in pediatric patients with severe renal impairment is 12.5 mg daily. Use in pediatric patients with ESRD is not recommended. (<linkHtml href="#LINK_ecc6b955-cc2a-42ca-a5d9-572b3ed9e223">2.6</linkHtml>, <linkHtml href="#LINK_fd505c6e-366b-45b0-8dd1-619bda0da840">8.6</linkHtml>) </item>
                           <item>Patients are advised to take consistently either with or without food. (<linkHtml href="#LINK_f05f6462-6bed-4ea9-b0a4-5487a0be7eb3">2.2</linkHtml>) </item>
                           <item>Administer upon awakening because the effects may last up to 16 hours and there is the potential for insomnia. (<linkHtml href="#LINK_f05f6462-6bed-4ea9-b0a4-5487a0be7eb3">2.2</linkHtml>) </item>
                           <item>Prior to treatment, assess for presence of cardiac disease. (<linkHtml href="#LINK_8a2f5435-8f70-4d07-9cd4-447fd5dfb9b4">2.1</linkHtml>) </item>
                           <item>To avoid substitution errors and overdosage, do not substitute for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and differing pharmacokinetic profiles. (<linkHtml href="#LINK_c60cebd2-178e-48b2-9e38-cafbd8384534">2.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_8a2f5435-8f70-4d07-9cd4-447fd5dfb9b4">
                     <id root="43996810-50b6-4efd-b2ca-3011bee02bf3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Pretreatment Screening</title>
                     <text>
                        <paragraph>Prior to treating patients with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, assess: </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b7cf7dd5-adb8-49df-88fd-cb523373f206">5.2</linkHtml>)]</content>
                           </item>
                           <item>the family history and clinically evaluate patients for motor or verbal tics or Tourettes syndrome before initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_f20d4ce6-ae6f-4d37-88d8-071aeecb2086">5.10</linkHtml>)]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f05f6462-6bed-4ea9-b0a4-5487a0be7eb3">
                     <id root="9852bb29-b503-4042-be93-5027eab913ab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 General Administration Information</title>
                     <text>
                        <paragraph>Because the effects of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may last up to 16 hours and there is potential for insomnia, administer once daily in the morning upon awakening. In the event of a missed dose, do not administer later in the day. Do not administer additional medication to make up for the missed dose <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_91834181-842a-4509-a170-fadb6fb4f07c">6.1</linkHtml>), Clinical Studies (<linkHtml href="#www.splportal.comLINK_05a592ef-2f31-471f-bb5c-1adc6415ed1f">14</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cd334e37-a606-44d4-a62a-28803f3ce575">
                     <id root="27917b97-dec8-4756-b953-304d2d6fe11e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Administration Instructions</title>
                     <text>
                        <paragraph>Administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules orally with or without food. Advise patients to take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules consistently either with food or without food <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">12.3</linkHtml>)]. </content>
                        </paragraph>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may be administered in one of the following ways: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Swallow dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules whole, or </item>
                           <item>Open capsule and sprinkle the entire contents over a spoonful of applesauce. The sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the sprinkled applesauce in its entirety without chewing. </item>
                           <item>The dose of a single capsule should not be divided. </item>
                        </list>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a33da779-ff9b-409a-97ba-32b4af09a232">
                     <id root="dcb3abe1-5a0e-4e54-bb27-ebc51a5149b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults (18 to 55 years)</content>
                        </paragraph>
                        <paragraph>The recommended starting dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules is 12.5 mg once daily in the morning upon awakening. Initial doses of 25 mg once daily may be considered for some patients. Dosage may be adjusted in increments of 12.5 mg no sooner than weekly, up to a maximum dose of 50 mg once daily, based on the therapeutic needs and response of the patient. Doses above 50 mg daily have shown no additional clinically meaningful benefit. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (13 to 17 years) </content>
                        </paragraph>
                        <paragraph>The recommended starting dose is 12.5 mg once daily in the morning upon awakening. Dosage may be adjusted in increments of 12.5 mg no sooner than weekly, up to a recommended maximum dose of 25 mg once daily. The dose should be individualized according to the needs and response of the patient. Doses higher than 25 mg have not been evaluated in clinical trials in pediatric patients. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_58d65a03-de7d-4ae8-8882-b4e8a332acd1">
                     <id root="9f0c9125-0a87-43eb-9448-5b9295316863"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications Due to Drug Interactions</title>
                     <text>
                        <paragraph>Agents that alter gastrointestinal and urinary pH can impact urinary excretion and alter blood levels of amphetamine. Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g., sodium bicarbonate) increase blood levels. Adjust dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule dosage accordingly <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ecc6b955-cc2a-42ca-a5d9-572b3ed9e223">
                     <id root="37743526-1607-4cb9-a21e-f9ea2dc8e4fc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>In adult patients with severe renal impairment (GFR between 15 to &lt;30 mL/min/1.73 m<sup>2</sup>), the recommended starting dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules is 12.5 mg daily with a maximum recommended dose of 25 mg daily. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are not recommended for use in patients with end stage renal disease (ESRD &lt;15 mL/min/1.73 m<sup>2</sup>). In pediatric patients (13 to 17 years) with severe renal impairment, the maximum dose is 12.5 mg, if tolerated <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_fd505c6e-366b-45b0-8dd1-619bda0da840">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">12.3</linkHtml>)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c60cebd2-178e-48b2-9e38-cafbd8384534">
                     <id root="9db688a5-7a87-4f05-8019-7c93a7b766f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Switching From Other Amphetamine Products</title>
                     <text>
                        <paragraph>For patients switching from another medication or any other amphetamine products, discontinue that treatment, and titrate with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules using the titration schedule <content styleCode="italics">[see Dosage and Administration <linkHtml href="#www.splportal.comLINK_a33da779-ff9b-409a-97ba-32b4af09a232">(2.4)</linkHtml>]</content>. </paragraph>
                        <paragraph>Do not substitute for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and differing pharmacokinetic profiles <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4d69c4bf-47ef-4354-9746-3729c48da1de">5.9</linkHtml>), Description (<linkHtml href="#www.splportal.comLINK_17119b33-31b4-4688-8b3b-b6fa919ed602">11</linkHtml>), Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_edc2ce16-d06a-42cf-8317-3e4f994c054c">
               <id root="a9dc0c7d-7e35-4ca4-ac44-ebf7a9af4d78"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disk">
                     <item>Extended-release capsules 12.5 mg: orange opaque cap and body, imprinted with A012 on both cap and body in black ink.</item>
                     <item>Extended-release capsules 25 mg: green opaque cap and body, imprinted with A025 on both cap and body in black ink.</item>
                     <item>Extended-release capsules 37.5 mg: blue-green opaquecap and body, imprinted with A038 on both cap and body in black ink.</item>
                     <item>Extended-release capsules 50 mg: blue opaque cap and body, imprinted with A049 on both cap and body in white ink.</item>
                  </list>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Extended-release capsules: 12.5 mg, 25 mg, 37.5 mg, 50 mg (<linkHtml href="#LINK_edc2ce16-d06a-42cf-8317-3e4f994c054c">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_be8d1088-0eff-4882-9919-b51eeecf1c65">
               <id root="5d9c3ab9-288e-44d7-bc17-ec1de04f60cc"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are contraindicated in patients with: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Known hypersensitivity to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_b49c21ed-9551-4986-bf81-a4d822cafd6a">6.2</linkHtml>)]</content>. </item>
                     <item>Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor, because of an increased risk of hypertensive crisis <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Known hypersensitivity to amphetamine products or other ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. <linkHtml href="#LINK_be8d1088-0eff-4882-9919-b51eeecf1c65">(4</linkHtml>) </item>
                           <item>Use with monoamine oxidase (MAO) inhibitors, or within 14 days of the last MAO inhibitor dose. (<linkHtml href="#LINK_be8d1088-0eff-4882-9919-b51eeecf1c65">4</linkHtml>, <linkHtml href="#LINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_b8ff5089-ffe4-4958-8dd5-2459cd087b7c">
               <id root="06a8a5d2-4720-448a-bb79-556e809397c6"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Risks to Patients with Serious Cardiac Disease: Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. (<linkHtml href="#LINK_b7cf7dd5-adb8-49df-88fd-cb523373f206">5.2</linkHtml>) </item>
                           <item>Increased Blood Pressure and Heart Rate: Monitor blood pressure and pulse. (<linkHtml href="#LINK_5ba479ab-d92c-4d44-8118-78a2b172fec7">5.3</linkHtml>) </item>
                           <item>Psychiatric Adverse Reactions: Prior to initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. (<linkHtml href="#LINK_9d33812b-73d6-4e9f-b4cb-385a4917959b">5.4</linkHtml>) </item>
                           <item>Long-Term Suppression of Growth in Pediatric Patients: Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted. (<linkHtml href="#LINK_865384f6-5503-4972-93b6-cad8a5d6f494">5.5</linkHtml>) </item>
                           <item>Peripheral Vasculopathy, Including Raynauds Phenomenon: Careful observation for digital changes is necessary during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. (<linkHtml href="#LINK_06f27598-8645-45aa-94cc-bfcbc6d480cc">5.6</linkHtml>) </item>
                           <item>Seizures: May lower the convulsive threshold. If a seizure occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. (<linkHtml href="#LINK_5e775066-0803-45e6-b561-43817bd1e23f">5.7</linkHtml>) </item>
                           <item>Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. If it occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and initiate supportive treatment. (<linkHtml href="#LINK_1c0b3f71-d71e-4272-b561-0bd73a8c61f2">5.8</linkHtml>)</item>
                           <item>Motor and Verbal Tics, and Worsening of Tourettes Syndrome: Before initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, assess the family history and clinically evaluate patients for tics or Tourettes syndrome. Regularly monitor patients for the emergence or worsening of tics or Tourettes syndrome. Discontinue treatment if clinically appropriate. (<linkHtml href="#LINK_f20d4ce6-ae6f-4d37-88d8-071aeecb2086">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_803928bf-e36e-434d-a9d8-35220fbb9f45">
                     <id root="bdf0782b-2eaa-4139-a067-7599292c6a4f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Abuse, Misuse, and
Addiction</title>
                     <text>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have a high potential for abuse and misuse. The use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules can be diverted for non-medical use into illicit channels or distribution<content styleCode="italics"> [see Drug Abuse and Dependence (<linkHtml href="#LINK_a55fd202-f540-43f4-97df-636d83602420">9.2</linkHtml>)]</content>. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                        <paragraph>Before prescribing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, assess each patients risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in a safe place, preferably locked, and instruct patients to not give dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules to anyone else. Throughout dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment, reassess each patients risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b7cf7dd5-adb8-49df-88fd-cb523373f206">
                     <id root="48e15561-0a2c-4032-9fcd-d89407bb6972"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Risks to
Patients with Serious Cardiac Disease</title>
                     <text>
                        <paragraph>Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage.</paragraph>
                        <paragraph>Avoid dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5ba479ab-d92c-4d44-8118-78a2b172fec7">
                     <id root="d8d3cd4c-6a56-4402-adf1-b445965fa3d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Increased Blood Pressure and Heart Rate</title>
                     <text>
                        <paragraph>CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mmHg) and heart rate (mean increase about 3 to 6 bpm). Some patients may have larger increases. </paragraph>
                        <paragraph>Monitor all dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules-treated patients for potential tachycardia and hypertension <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_91834181-842a-4509-a170-fadb6fb4f07c">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9d33812b-73d6-4e9f-b4cb-385a4917959b">
                     <id root="c49b66f0-c2b6-4849-8e03-3f6d95723d06"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Psychiatric Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Exacerbation of Pre-Existing Psychosis </content>
                        </paragraph>
                        <paragraph>CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Induction of a Manic Episode in Patients with Bipolar Disorder </content>
                        </paragraph>
                        <paragraph>CNS stimulants may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).</paragraph>
                        <paragraph>
                           <content styleCode="underline">New Psychotic or Manic Symptoms </content>
                        </paragraph>
                        <paragraph>CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_865384f6-5503-4972-93b6-cad8a5d6f494">
                     <id root="2a0ea1d4-2c68-4531-b7b4-2a36d50019ed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Long-Term Suppression of Growthin Pediatric Patients</title>
                     <text>
                        <paragraph>CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.</paragraph>
                        <paragraph> In a 4 week, placebo-controlled trial of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in patients ages 6 to 17 years old with ADHD, there was a decrease in weight in the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules groups compared to weight gain in the placebo group <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_91834181-842a-4509-a170-fadb6fb4f07c">6.1</linkHtml>)]</content>. </paragraph>
                        <paragraph>Closely monitor growth (weight and height) in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules-treated pediatric patients. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are not approved for use in pediatric patients 12 years and younger <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9eaee862-6b45-4124-b737-68f869e0d1a1">8.4</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_06f27598-8645-45aa-94cc-bfcbc6d480cc">
                     <id root="a8ee4ef3-8a83-4483-a872-417b23d91d01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Peripheral Vasculopathy, Including Raynauds Phenomenon</title>
                     <text>
                        <paragraph>CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, used to treat ADHD are associated with peripheral vasculopathy, including Raynauds phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynauds phenomenon, were observed in postmarketing reports and at the therapeutic dosage of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant.</paragraph>
                        <paragraph>Careful observation for digital changes is necessary during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules-treated patients who develop signs or symptoms of peripheral vasculopathy.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5e775066-0803-45e6-b561-43817bd1e23f">
                     <id root="a5b40184-0330-491d-a829-06febafd8b25"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Seizures</title>
                     <text>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in the absence of seizures, and in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules should be discontinued. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1c0b3f71-d71e-4272-b561-0bd73a8c61f2">
                     <id root="c3fe3cd4-f70c-4392-bd4f-b28303730c9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Serotonin Syndrome</title>
                     <text>
                        <paragraph>Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. Johns Wort <content styleCode="italics">[see Drug Interactions (7.1)]</content>. The coadministration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk with increased exposure to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. In these situations, consider an alternative nonserotonergic drug or an alternative drug that does not inhibit CYP2D6 <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1)</linkHtml>]</content>. </paragraph>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). </paragraph>
                        <paragraph>Concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules with MAOI drugs is contraindicated <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_be8d1088-0eff-4882-9919-b51eeecf1c65">4</linkHtml>)]</content>. </paragraph>
                        <paragraph>Discontinue treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4d69c4bf-47ef-4354-9746-3729c48da1de">
                     <id root="2819d582-cd52-46ec-97dc-6e59d751c503"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Potential for Overdose Due to Medication Errors</title>
                     <text>
                        <paragraph>Medication errors, including substitution and dispensing errors, between dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and other amphetamine products could occur, leading to possible overdosage. To avoid substitution errors and overdosage, do not substitute for other amphetamine products on a milligram-per-milligram basis because of different amphetamine base compositions and differing pharmacokinetic profiles <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_c60cebd2-178e-48b2-9e38-cafbd8384534">2.7</linkHtml>), Overdosage (<linkHtml href="#www.splportal.comLINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">10</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bcf56592-0b59-402f-8c0c-fc3810a2d398">
                     <id root="fbdbe1a5-ae07-4b71-9004-6fbcc022295e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Motor and Verbal Tics, and Worsening of Tourettes Syndrome</title>
                     <text>
                        <paragraph>CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourettes syndrome has also been reported<content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_b49c21ed-9551-4986-bf81-a4d822cafd6a">6.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Before initiating dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, assess the family history and clinically evaluate patients for tics or Tourettes syndrome. Regularly monitor dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules-treated patients for the emergence or worsening of tics or Tourettes syndrome, and discontinue treatment if clinically appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5ac8a749-8b6f-43f8-8a9e-2667d1ae52fa">
               <id root="87abac22-3dd4-4424-b7b4-1e65f2a653bf"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Abuse, Misuse, and Addiction<content styleCode="italics">[see Boxed Warning, Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_803928bf-e36e-434d-a9d8-35220fbb9f45">5.1</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#www.splportal.comLINK_a55fd202-f540-43f4-97df-636d83602420">9.2</linkHtml>, <linkHtml href="#www.splportal.comLINK_04c15c5d-20d1-4e78-a0e0-a1242f7b6637">9.3</linkHtml>)] </content>
                     </item>
                     <item>Hypersensitivity to amphetamine products or other ingredients of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_be8d1088-0eff-4882-9919-b51eeecf1c65">4</linkHtml>)] </content>
                     </item>
                     <item>Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_be8d1088-0eff-4882-9919-b51eeecf1c65">4</linkHtml>), Drug Interactions (<linkHtml href="#www.splportal.comLINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)]</content>
                     </item>
                     <item>Risks to Patients withSeriousCardiac Disease<content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_b7cf7dd5-adb8-49df-88fd-cb523373f206">5.2</linkHtml>)]</content>
                     </item>
                     <item>Increased Blood Pressure and Heart Rate<content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5ba479ab-d92c-4d44-8118-78a2b172fec7">5.3</linkHtml>)]</content>
                     </item>
                     <item>Psychiatric Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_9d33812b-73d6-4e9f-b4cb-385a4917959b">5.4</linkHtml>)]</content>
                     </item>
                     <item>Long-Term Suppression of Growth in Pediatric Patients<content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_865384f6-5503-4972-93b6-cad8a5d6f494">5.5</linkHtml>)]</content>
                     </item>
                     <item>Peripheral Vasculopathy, Including Raynauds Phenomenon <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_06f27598-8645-45aa-94cc-bfcbc6d480cc">5.6</linkHtml>)]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5e775066-0803-45e6-b561-43817bd1e23f">5.7</linkHtml>)]</content>
                     </item>
                     <item>Serotonin Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_1c0b3f71-d71e-4272-b561-0bd73a8c61f2">5.8</linkHtml>)]</content>
                     </item>
                     <item>Motor and Verbal Tics, and Worsening of Tourettes Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_f20d4ce6-ae6f-4d37-88d8-071aeecb2086">5.10</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions in patients with ADHD (incidence 5% and at a rate at least twice placebo) are: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Pediatrics (13 years and older): insomnia, decreased appetite, decreased weight, irritability, and nausea. (<linkHtml href="#LINK_91834181-842a-4509-a170-fadb6fb4f07c">6.1</linkHtml>) </item>
                           <item>Adults: insomnia, decreased appetite, decreased weight, dry mouth, increased heart rate, and anxiety. <linkHtml href="#LINK_91834181-842a-4509-a170-fadb6fb4f07c">(6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">
                              <content styleCode="bold">Teva </content>
                              <content styleCode="bold">at 1-888-838-2872</content>
                           </content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_91834181-842a-4509-a170-fadb6fb4f07c">
                     <id root="45c93664-81ea-468a-8122-28b8e2c5ff74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. </paragraph>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules were studied in adults (18 to 55 years) and pediatric patients (13 to 17 years) who met Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> or 5<sup>th</sup> editions (DSM-IV-TR<sup></sup> or DSM-5) criteria for ADHD. The safety data for adults were pooled from three randomized, double-blind, placebo-controlled studies in doses of 12.5 mg to 75 mg per day (1.5 times the maximum recommended dosage). Doses higher than 50 mg per day did not demonstrate additional clinical benefit and are not recommended. </paragraph>
                        <paragraph>The safety data for pediatric patients (13 to 17 years) is from 1 randomized, double-blind, placebo-controlled study of doses of 12.5 mg to 25 mg. The total exposure in patients treated with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules totalled 704; this included pediatric patients, 78 adolescent patients and 626 adult patients from multiple well-controlled trials. The duration of use ranged from 4 to 7 weeks <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_05a592ef-2f31-471f-bb5c-1adc6415ed1f">14</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation of Treatment </content>
                        </paragraph>
                        <paragraph>In pooled controlled trials of adult patients, 9% (54/626) of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule-treated patients discontinued due to adverse reactions compared to 2% (7/328) of placebo-treated patients. The most frequent adverse reactions leading to discontinuation (i.e., leading to discontinuation in at least 1% of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule-treated patients and at a rate at least twice that of placebo) were insomnia (2%, n=15), blood pressure increased (2%, n=10), decreased appetite (1%, n=5), and headache (1%, n=4). </paragraph>
                        <paragraph>In a controlled trial including adolescent patients (13 to 17 years), 5% (4/78) of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule-treated patients discontinued due to adverse reactions compared to 0% (0/79) of placebo-treated patients. The most frequent adverse reaction leading to discontinuation (i.e., leading to discontinuation in at least 1% of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule-treated patients and at a rate at least twice that of placebo) were dizziness (1%, n=1), depression (1%, n=1), abdominal pain upper (1%, n=1), and viral infection (1%, n=1). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Occurring at an Incidence of 2% and at Least Twice Placebo Among Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsule-Treated Adults in Clinical Trials </content>
                        </paragraph>
                        <paragraph>The most common adverse reactions reported in adults were insomnia, decreased appetite, dry mouth, decreased weight, heart rate increased, and anxiety. <content styleCode="italics">Table 1</content> lists the adverse reactions that occurred 2% compared to placebo. The most common adverse reaction (insomnia) generally occurred early during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.</paragraph>
                        <table>
                           <caption>Table 1: Adverse Reactions Reported by 2% or More of Adults Taking Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules and at Least Twice the Incidence in Patients Taking Placebo in 3 Clinical Trials (4, 6, and 7 Weeks)</caption>
                           <col width="32%"/>
                           <col width="20%"/>
                           <col width="38%"/>
                           <col width="11%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Body System </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules*</content>
                                       <content styleCode="bold">
                                          <br/>
            (N = 626)</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo <br/>
            (N = 328) </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Nervous System</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Anxiety </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Feeling Jittery </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Agitation </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Bruxism </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Psychiatric Disorders</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Insomnia </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>31%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Depression </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Metabolism and Nutritional Disorders</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Decreased Appetite </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>30%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Weight Decreased </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Gastrointestinal System</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dry Mouth </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>23%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Diarrhea </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Cardiovascular System</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Heart Rate Increased </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Palpitations </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Genitourinary System </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dysmenorrhea<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Erectile Dysfunction<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4"><sup>*</sup> Includes doses up to 75 mg (1.5 times the maximum recommended dosage).</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4"><sup>a</sup>Dysmenorrhea was observed in 11 females.</td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4"><sup>b</sup>Erectile dysfunction was observed in 6 males.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Occurring at an Incidence of 2% or More and at Least Twice Placebo Among Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsule-Treated Adolescents (13 to 17 years) in a 4 Week Clinical Trial </content>
                        </paragraph>
                        <paragraph>The most common adverse reactions reported in adolescents were decreased appetite, nausea, insomnia, abdominal pain upper, irritability, and weight decreased. <content styleCode="italics">Table 2</content> lists the adverse reactions that occurred 2% compared to placebo.</paragraph>
                        <table>
                           <caption>Table 2: Adverse Reactions Reported by 2% or More of Adolescents Taking Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules and at Least Twice the Incidence in Patients Taking Placebo in a 4 Week Clinical Trial</caption>
                           <col width="17%"/>
                           <col width="23%"/>
                           <col width="47%"/>
                           <col width="12%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Body System</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules <br/>
            (N = 78)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo <br/>
            (N = 79)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Nervous System</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Metabolism and Nutrition Disorders</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Decreased appetite</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>22%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Weight decreased</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Psychiatric Disorders</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Irritability</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Insomnia*</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Gastrointestinal Disorders</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abdominal pain upper</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="4"><sup>*</sup>Insomnia includes terms: initial insomnia, middle insomnia, terminal insomnia and insomnia.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b49c21ed-9551-4986-bf81-a4d822cafd6a">
                     <id root="dda21927-6d94-4ebc-8cbe-c998453f6481"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Adverse Reactions Associated with the Use of Amphetamines</title>
                     <text>
                        <paragraph>The following adverse reactions have been associated with the use of amphetamines. The following adverse reactions have been identified during postapproval use of amphetamines. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Allergic:</content> Urticaria, rash, hypersensitivity reactions, including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular:</content> Dyspnea, sudden death. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Central Nervous System:</content> Psychotic episodes at recommended doses, overstimulation, restlessness, euphoria, dyskinesia, dysphoria, headache, tics, fatigue, aggression, anger, logorrhea, dermatillomania, and paresthesia (including formication), motor and verbal tics.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine:</content> Impotence, changes in libido, frequent or prolonged erections. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> Mydriasis. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> Unpleasant taste, constipation, intestinal ischemia. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders:</content> Rhabdomyolysis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin:</content> Alopecia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content> Raynauds phenomenon. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_62ee8335-fd58-4195-9011-e794165698ee">
               <id root="761178d4-bb6b-43ac-8dec-2bb28a0a6622"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Acidifying and Alkalinizing Agents: Agents that alter GI and urinary pH can alter blood levels of amphetamine. Acidifying agents (GI and urinary) decrease amphetamine blood levels, while alkalinizing agents (GI and urinary) increase amphetamine blood levels. Adjust dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule dosage accordingly. (<linkHtml href="#LINK_58d65a03-de7d-4ae8-8882-b4e8a332acd1">2.5</linkHtml>, <linkHtml href="#LINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">
                     <id root="1308b6df-83e8-44ac-a9c6-a8e9ddb6e07e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs Having Clinically Important Interactions with Amphetamines</title>
                     <text>
                        <table>
                           <caption>Table 3: Drugs Having Clinically Important Interactions with Amphetamines</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="italics"></content>
                                          <content styleCode="bold">Monoamine Oxidase Inhibitors<content styleCode="italics"></content>
                                          </content>(MAOIs)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules during or within 14 days following the administration of MAOI <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_be8d1088-0eff-4882-9919-b51eeecf1c65">4</linkHtml>)]. </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Serotonergic Drugs</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>The concomitant use of amphetamines and serotonergic drugs increases the risk of serotonin syndrome. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and concomitant serotonergic drug(s) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5e775066-0803-45e6-b561-43817bd1e23f">5.7</linkHtml>)].</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Alkalinizing Agents</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>May increase exposure to amphetamine and exacerbate the action of amphetamine. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Caution should be taken when coadministering dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and gastrointestinal and urinary alkalinizing agents. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Acidifying Agents</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Lower blood levels and efficacy of amphetamines. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Increase dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules based on clinical response. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Tricyclic Antidepressants</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of <content styleCode="italics">d</content>-amphetamine in the brain; cardiovascular effects can be potentiated. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Monitor frequently and adjust dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules dose or use alternative therapy based on clinical response. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">CYP2D6 Inhibitors</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>May increase the exposure of amphetamine.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Start with lower doses and monitor frequently and adjust dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules dose or use alternative therapy based on clinical response. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" colspan="2" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Gastric pH Modulators</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Clinical Impact </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Potential change in shape of PK profile and exposure may occur.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>Intervention </paragraph>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Monitor patients for changes in clinical effect and use alternative therapy based on clinical response. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dffe4e0d-5879-4e32-8800-299a5e4a60fd">
                     <id root="c224f123-3b6f-4c24-9902-19d37de5e05b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cb176fc1-81b7-4bf3-9dce-5d122719993a">
               <id root="df570e59-0906-4428-84b8-426a133207c1"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Pregnancy: Based on animal data, may cause fetal harm. (<linkHtml href="#LINK_9361a3c9-46cd-4baf-82d3-79bf4953f6ca">8.1</linkHtml>) </item>
                           <item>Lactation: Breastfeeding not recommended. (<linkHtml href="#LINK_6196e00d-1643-48e9-935e-498cfd4c5fc2">8.2</linkHtml>)</item>
                           <item>Pediatric: Safety and effectiveness have not been established in pediatric patients ages 12 years and younger. (<linkHtml href="#LINK_9eaee862-6b45-4124-b737-68f869e0d1a1">8.4</linkHtml>)</item>
                           <item>Renal Impairment: Dose adjustment is needed in patients with severe renal insufficiency. Use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in patients with ESRD is not recommended. (<linkHtml href="#LINK_ecc6b955-cc2a-42ca-a5d9-572b3ed9e223">2.6</linkHtml>, <linkHtml href="#LINK_fd505c6e-366b-45b0-8dd1-619bda0da840">8.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9361a3c9-46cd-4baf-82d3-79bf4953f6ca">
                     <id root="5a293a99-ea87-455a-bac9-10a41e83ba47"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The limited available data from published literature and postmarketing reports on use of amphetamine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. Adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers dependent on amphetamines <content styleCode="italics">[see Clinical Considerations].</content>
                        </paragraph>
                        <paragraph>In an embryofetal development study, amphetamine (<content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- enantiomer ratio of 3:1, the same as in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules) had no effects on embryofetal morphological development or survival when administered to pregnant rats and rabbits throughout the period of organogenesis up to doses 10 times the maximum recommended human dose (MRHD) of 25 mg/day given to adolescents, on a mg/m<sup>2</sup> body surface area basis. However, in a pre- and postnatal development study, amphetamine (<content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- ratio of 3:1) administered orally to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine. In addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine. Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine <content styleCode="italics">[see Data]. </content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Amphetamines, such as dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, cause vasoconstriction and thereby may decrease placental perfusion. In addition, amphetamines can stimulate uterine contractions increasing the risk of premature delivery. Infants born to amphetamine-dependent mothers have an increased risk of premature delivery and low birth weight. </paragraph>
                        <paragraph>Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Amphetamine (<content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- enantiomer ratio of 3:1, the same as in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules) had no apparent effects on embryofetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. These doses are approximately 2 and 10 times, respectively, the maximum recommended human dose (MRHD) of 25 mg/day given to adolescents, on a mg/m<sup>2</sup> body surface area basis. Fetal malformations and death have been reported in mice following parenteral administration of <content styleCode="italics">d</content>-amphetamine doses of 50 mg/kg/day (approximately 8 times the MRHD given to adolescents on a mg/m<sup>2</sup> basis) or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity. </paragraph>
                        <paragraph>A pre- and postnatal development study was conducted with amphetamine (<content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- enantiomer ratio of 3:1) in which pregnant rats received daily oral doses of 2, 6, and 10 mg/kg from gestation Day 6 to lactation Day 20. These doses are approximately 0.6, 2, and 3 times the MRHD of 25 mg/day amphetamine (<content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- ratio of 3:1) given to adolescents, on a mg/m<sup>2</sup> basis. All doses caused hyperactivity and decreased weight gain in the dams. A decrease in pup survival was seen at all doses. A decrease in pup body weight was seen at 6 and 10 mg/kg which correlated with delays in developmental landmarks, such as preputial separation and vaginal opening. Increased pup locomotor activity was seen at 10 mg/kg on Day 22 postpartum but not at 5 weeks postweaning. When pups were tested for reproductive performance at maturation, gestational weight gain, number of implantations, and number of delivered pups were decreased in the group whose mothers had been given 10 mg/kg. </paragraph>
                        <paragraph>A number of studies from the literature in rodents indicate that prenatal or early postnatal exposure to amphetamine (<content styleCode="italics">d</content>- or <content styleCode="italics">d</content>, <content styleCode="italics">l</content>-) at doses similar to those used clinically can result in long-term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6196e00d-1643-48e9-935e-498cfd4c5fc2">
                     <id root="fabe6fa6-fa8e-4729-a8b0-796e2f5d463a"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Based on limited case reports in published literature, amphetamine (<content styleCode="italics">d</content>- or <content styleCode="italics">d</content>, <content styleCode="italics">l</content>-) is present in human milk, at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large dosages of dextroamphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9eaee862-6b45-4124-b737-68f869e0d1a1">
                     <id root="ed097f96-1ee1-4fb9-ad33-7829860701bf"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in pediatric patients with ADHD ages 13 to 17 years have been established in two placebo-controlled clinical studies <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_91834181-842a-4509-a170-fadb6fb4f07c">6.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#LINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">12.3</linkHtml>), Clinical Studies (<linkHtml href="#LINK_05a592ef-2f31-471f-bb5c-1adc6415ed1f">14</linkHtml>)]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have not been established in pediatric patients ages 12 years and younger. </paragraph>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have been studied for the treatment of ADHD in pediatric patients 6 to 12 years in two placebo controlled safety and efficacy trials. In the first trial, pediatric patients 6 to 12 years experienced higher rates of adverse reactions in some cases compared to patients 13 years and older, including higher rates of insomnia (30% vs 8%) and appetite decreased (43% vs 22%). In addition, amphetamine systemic exposures (both d- and l-) in pediatric patients 6 to 12 years following a single dose were higher than those observed in adults at the same dose (72% to 79% higher C<sub>max</sub> and approximately 83% higher AUC). A second trial evaluated a lower dose than those approved for pediatric patients 13 to 17 years; efficacy was not demonstrated for the lower dose. Therefore, a safe and effective dose cannot be established in pediatric patients 12 years and younger.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Growth Suppression </content>
                        </paragraph>
                        <paragraph>Growth should be monitored during treatment with stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, in pediatric patients 13 to 17 years who are not growing or gaining weight as expected may need to have their treatment interrupted <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_865384f6-5503-4972-93b6-cad8a5d6f494">5.5)</linkHtml>, Adverse Reactions (<linkHtml href="#www.splportal.comLINK_91834181-842a-4509-a170-fadb6fb4f07c">6.1</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Toxicity Data </content>
                        </paragraph>
                        <paragraph>Juvenile rats treated with mixed amphetamine salts (same as in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules) early in the postnatal period through sexual maturation demonstrated transient changes in motor activity. Learning and memory was impaired at approximately 8 times the maximum recommended human dose (MRHD) given to children on a mg/m<sup>2</sup> basis. No recovery was seen following a drug-free period. A delay in sexual maturation was observed at a dose approximately 8 times the MRHD given to children on a mg/m<sup>2</sup> basis, although there was no effect on fertility. </paragraph>
                        <paragraph>In a juvenile developmental study, rats received daily oral doses of amphetamine (<content styleCode="italics">d</content> to <content styleCode="italics">l</content> enantiomer ratio of 3:1, the same as in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules) of 2, 6, or 20 mg/kg on days 7 to 13 of age; from Day 14 to approximately Day 60 of age these doses were given b.i.d. for total daily doses of 4, 12, or 40 mg/kg. The latter doses are approximately 0.8, 2, and 8 times the MRHD of 25 mg/day given to children on a mg/m<sup>2</sup> basis. Postdosing hyperactivity was seen at all doses; motor activity measured prior to the daily dose was decreased during the dosing period but the decreased motor activity was largely absent after an 18 day drug-free recovery period. Performance in the Morris water maze test for learning and memory was impaired at the 40 mg/kg dose, and sporadically at the lower doses, when measured prior to the daily dose during the treatment period; no recovery was seen after a 19 day drug-free period. A delay in the developmental milestones of vaginal opening and preputial separation was seen at 40 mg/kg but there was no effect on fertility.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_201ca449-a81e-4012-834e-43d5b31d65e6">
                     <id root="bf1e2032-af37-41d9-8801-3a1e61df26da"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fd505c6e-366b-45b0-8dd1-619bda0da840">
                     <id root="6c5af285-ebbb-41a5-a702-64895598bd46"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Due to reduced clearance of amphetamine in patients with severe renal insufficiency (GFR 15 to &lt;30 mL/min/1.73 m<sup>2</sup>), the maximum dose in adults should be reduced. Pediatric patients ages 13 to 17 years with severe renal insufficiency can be given the recommended starting dose if tolerated, but the dose should not be escalated. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are not recommended in patients with ESRD (GFR &lt;15 mL/min/1.73 m<sup>2</sup>) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_ecc6b955-cc2a-42ca-a5d9-572b3ed9e223">2.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">12.3</linkHtml>)]</content>. </paragraph>
                        <paragraph>d-Amphetamine is not dialyzable.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e03d9201-6cae-4b07-832b-3c4b016c8830">
               <id root="87a4510b-aa24-42bf-ab5c-4618ab9c551d"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <text/>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="LINK_68db25d5-f459-43d7-9af4-cdd4fe54fccc">
                     <id root="021b73a6-a9a1-43a8-8d3a-5d801b135300"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules contain mixed amphetamine salts, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a55fd202-f540-43f4-97df-636d83602420">
                     <id root="56c99d60-79b2-4067-be1c-8d4e1a49f1a3"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_803928bf-e36e-434d-a9d8-35220fbb9f45">5.1</linkHtml>)]</content>. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                        <paragraph>Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                        <paragraph>Misuse and abuse of amphetamine may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_04c15c5d-20d1-4e78-a0e0-a1242f7b6637">
                     <id root="d127d1e0-cd78-4d5d-8493-0083812fcf4e"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Physical Dependence</content>
                        </paragraph>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph>Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tolerance </content>
                        </paragraph>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">
               <id root="73818e28-8a85-4223-beb1-22ce6c26c4cf"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Effects of Overdose </content>
                  </paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                     <item>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                     <item>Life-threatening hyperthermia (temperatures greater than 104F) and rhabdomyolysis may develop. </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Overdose Management</content>
                  </paragraph>
                  <paragraph>Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules should be considered when treating patients with overdose. D-amphetamine is not dialyzable. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="LINK_17119b33-31b4-4688-8b3b-b6fa919ed602">
               <id root="c6db2002-d15b-45d0-96c3-b17db9ebe9e0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules contain mixed salts of a single-entity amphetamine, a CNS stimulant. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules contain equal amounts (by weight) of four salts: dextroamphetamine sulfate and amphetamine sulfate, dextroamphetamine saccharate and amphetamine aspartate monohydrate. This results in a 3:1 mixture of dextro- to levo- amphetamine base equivalent. </paragraph>
                  <paragraph>The 12.5 mg, 25 mg, 37.5 mg and 50 mg strength capsules are for oral administration. They are designed to contain two types of drug extended release pellets. One type of extended release pellets contains an outer coating of drug to immediately release drug upon administration.</paragraph>
                  <table width="700px">
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode=" Botrule Toprule"/>
                           <td align="center" valign="top" colspan="3" styleCode=" Botrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">CAPSULE STRENGTHS</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule Toprule"/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">EACH CAPSULE CONTAINS: </content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">12.5 mg </content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">25 mg </content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">37.5 mg </content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">50 mg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Toprule">
                              <paragraph>Dextroamphetamine Saccharate </paragraph>
                           </td>
                           <td valign="top" styleCode=" Toprule">
                              <paragraph>3.125 mg </paragraph>
                           </td>
                           <td valign="top" styleCode=" Toprule">
                              <paragraph>6.250 mg </paragraph>
                           </td>
                           <td valign="top" styleCode=" Toprule">
                              <paragraph>9.375 mg </paragraph>
                           </td>
                           <td valign="top" styleCode=" Toprule">
                              <paragraph>12.500 mg </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Amphetamine Aspartate Monohydrate </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>3.125 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>6.250 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>9.375 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>12.500 mg </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Dextroamphetamine Sulfate </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>3.125 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>6.250 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>9.375 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>12.500 mg </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Amphetamine Sulfate</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>3.125 mg</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>6.250 mg</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>9.375 mg</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>12.500 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Total mixed amphetamine salts</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>12.500 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>25 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>37.5 mg </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>50 mg </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Botrule">
                              <paragraph>Total amphetamine base equivalence</paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule">
                              <paragraph>7.8 mg</paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule">
                              <paragraph>15.6 mg</paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule">
                              <paragraph>23.5 mg</paragraph>
                           </td>
                           <td valign="top" styleCode=" Botrule">
                              <paragraph>31.3 mg</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Inactive Ingredients</content>: ethylcellulose, hypromellose 2910, iron oxide red, iron oxide yellow, methacrylic acid copolymer dispersion; methyl acrylate, methyl methacrylate, and methacrylic acid copolymer; polyethylene glycol 400, polysorbate 80, sugar spheres (which contains corn starch and sucrose), talc, titanium dioxide, and triethyl citrate. The capsule shells contain gelatin, sodium lauryl sulfate, titanium dioxide. In addition, the 12.5 mg capsule shell contains carboxymethylcellulose, iron oxide red, and iron oxide yellow; the 25 mg capsule shell contains carboxymethylcellulose, FD&amp;C Blue #1, iron oxide red, and iron oxide yellow; the 37.5 mg capsule shell contains carboxymethylcellulose, FD&amp;C Blue #1 and FD&amp;C Red #40, and iron oxide red; 50 mg capsule shell contains FD&amp;C Blue #1 and FD&amp;C Red #40. The printing ink for 12.5 mg, 25 mg, and 37.5 mg capsule contains ammonium hydroxide, iron oxide black, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution. The printing ink for the 50 mg capsule contains ammonium hydroxide, povidone, propylene glycol, simethicone (which contains dimethicone and silicon dioxide), shellac, sodium hydroxide, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="LINK_370dfb1a-205a-4171-88b6-a23ab0a71090">
               <id root="a1d64451-27d0-4786-bc45-4b08761d068c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="LINK_73fa4457-a391-427f-97cd-fc17ae671173">
                     <id root="e747fefa-6c4e-461a-9cb5-8987b549483b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_06e5d95b-3867-43b2-a250-3c1aa7198cc8">
                     <id root="a9cb59c4-e08a-4cf9-94ed-2da340f05e1b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">
                     <id root="55d2dc12-1f00-467c-a4d2-41983a276c3f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules contain <content styleCode="italics">d</content>-amphetamine and <content styleCode="italics">l</content>-amphetamine salts in the ratio of 3:1. Pharmacokinetic studies of <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine after oral administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules have been conducted in healthy adults (19 to 52 years) and pediatric patients (6 to 17 years) with ADHD. Following administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, the peak plasma concentrations occurred in about 7 to 10 hours in pediatric patients and about 8 hours in adults for both <content styleCode="italics">d</content>-amphetamine and <content styleCode="italics">l</content>-amphetamine. The mean plasma elimination half-life for <content styleCode="italics">d</content>-amphetamine ranges from about 10 to 11 hours and <content styleCode="italics">l</content>-amphetamine from 10 to 13 hours in both pediatric and adult patients. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption </content>
                        </paragraph>
                        <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules exhibit linear dose proportionality over the range of 12.5 to 50 mg. Steady-state is achieved between Days 7 and 8 of dosing with mean accumulation ratio of 1.6. A single dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules 37.5 mg capsules provided comparable plasma concentration profiles of both <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine to mixed amphetamine salts extended release (MAS-ER) 25 mg followed by 12.5 mg immediate release amphetamine administered 8 hours later <content styleCode="italics">(Figure 1)</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1: Mean Plasma Concentrations of<content styleCode="italics"> d- </content>and<content styleCode="italics"> l-</content>amphetamine Following Oral Administration of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules 37.5 mg vs MAS-ER 25 mg Followed by Immediate-Release MAS-IR 12.5 mg 8 Hours Later in Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <renderMultiMedia referencedObject="MM1"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food </content>
                        </paragraph>
                        <paragraph>High fat meal does not affect the extent of absorption of <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine when taken with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. T<sub>max</sub> is prolonged by 5 hours (from 7.0 hours at fasted state to 12.0 hours after a high-fat meal) for <content styleCode="italics">d</content>-amphetamine and 4.5 hours (from 7.5 hours at fasted state to 12 hours after a high-fat meal) for <content styleCode="italics">l</content>-amphetamine after administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules 50 mg with high fat meal. Opening the capsule and sprinkling the contents on applesauce results in comparable absorption and exposure to the intact capsule taken in the fasted state <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_cd334e37-a606-44d4-a62a-28803f3ce575">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Alcohol </content>
                        </paragraph>
                        <paragraph>The <content styleCode="italics">in vitro</content> testing showed increases in amphetamine release rate from dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in the presence of 20% and, more noticeably, 40% alcohol. There is no <content styleCode="italics">in vivo </content>study conducted for the effect of alcohol on drug exposure. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism </content>
                        </paragraph>
                        <paragraph>Amphetamine is reported to be oxidized at the 4 position of the benzene ring to form 4-hydroxyamphetamine, or on the side chain <content styleCode="italics"></content> or <content styleCode="italics"></content> carbons to form alpha-hydroxy-amphetamine or norephedrine, respectively. Norephedrine and 4-hydroxy-amphetamine are both active and each is subsequently oxidized to form 4-hydroxy-norephedrine. Alpha-hydroxy-amphetamine undergoes deamination to form phenylacetone, which ultimately forms benzoic acid and its glucuronide and the glycine conjugate hippuric acid. Although the enzymes involved in amphetamine metabolism have not yet been clearly defined, CYP2D6 is known to be involved with formation of 4-hydroxy-aphetamine. Since CYP2D6 is genetically polymorphic, population variations in amphetamine metabolism are a possibility. </paragraph>
                        <paragraph>Amphetamine is known to inhibit monoamine oxidase. Amphetamines are not an <content styleCode="italics">in vitro</content> inhibitor of the major human CYP450 isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), nor was it an <content styleCode="italics">in vitro</content> inducer of CYP1A2, CYP2B6 or CYP3A4/5. Amphetamines are not an <content styleCode="italics">in vitro</content> substrate for P-gp. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>The renal excretion is the primary route for elimination of <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine and its metabolites after administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. </paragraph>
                        <paragraph>At normal urine pHs, approximately half of an administered dose of amphetamine is recoverable in urine as derivatives of alpha-hydroxy-amphetamine and approximately another 30% to 40% of the dose is recoverable in urine as amphetamine itself. Urinary recovery of amphetamine is highly dependent on pH and urine flow rates. Alkaline urine pHs result in less ionization and reduced renal elimination, and acidic pHs and high flow rates result in increased renal elimination. Urinary recovery of amphetamine has been reported to range from 1% to 75%, and the fraction of a dose hepatically metabolized is dependent on urine pH. Consequently, both hepatic and renal dysfunctions have the potential to alter the elimination of amphetamine and could result in prolonged exposures <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Age </content>
                        </paragraph>
                        <paragraph>Comparison of the pharmacokinetics of <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine after oral administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in pediatric patients with ADHD 13 to 17 years old and healthy adult subjects (19 to 52 years) indicates that body weight is the primary determinant of apparent differences in the pharmacokinetics of <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine across the age range. </paragraph>
                        <paragraph>PK data from patients age 13 to 17 years (n=14) who received a single 25 mg dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule was scaled (based on PK proportionality) and compared with PK data from adult patients 19 to 51 years (n=20) who received 37.5 mg. Based on dose proportionality, a single-dose dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule administered to pediatric patients age 13 to 17 years (n=14) would produce about 21% to 31% higher C<sub>max</sub> for <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine and 21% to 31% higher AUC for <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine, compared to the same dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsule administered to adults (age 19 to 51 years). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients </content>
                        </paragraph>
                        <paragraph>In pharmacokinetic studies, systemic exposure to <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine was similar in women (N=41) and in men (N=61). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Racial Groups </content>
                        </paragraph>
                        <paragraph>Formal pharmacokinetic studies for race have not been conducted. However, amphetamine pharmacokinetics appeared to be comparable among Whites (N=41), Blacks (N=27), and Hispanics (N=34). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal impairment </content>
                        </paragraph>
                        <paragraph>The effect of renal impairment on <content styleCode="italics">d</content>- and <content styleCode="italics">l</content>-amphetamine after administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules has not been studied. </paragraph>
                        <paragraph>In a pharmacokinetic study of lisdexamfetamine in adult subjects with normal and impaired renal function mean <content styleCode="italics">d</content>-amphetamine clearance was reduced from 0.7 L/hr/kg in normal subjects to 0.4 L/hr/kg in subjects with severe renal impairment (GFR 15 to &lt;30 mL/min/1.73 m<sup>2</sup>) patients. Dialysis did not significantly affect the clearance of <content styleCode="italics">d</content>-amphetamine. The impact of renal impairment on the disposition of amphetamine would be expected to be similar between oral administration of lisdexamfetamine and dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_fd505c6e-366b-45b0-8dd1-619bda0da840">8.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_19be1eaa-02dd-4a5a-8ca7-8d9d96306b5a">
               <id root="66a732ec-d9f1-4eac-84d9-59fa85804a93"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="LINK_160c58fc-c221-4e74-b3ce-d98cc5449915">
                     <id root="231afd31-8871-492b-9585-37b633eb8f60"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis </content>
                        </paragraph>
                        <paragraph>No evidence of carcinogenicity was found in studies in which <content styleCode="italics">d</content>, <content styleCode="italics">l</content>-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 3, 2, and 1 times, respectively, the maximum recommended human dose of 50 mg/day on a mg/m<sup>2</sup> body surface area basis in adults. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Amphetamine, in the enantiomer ratio present, <content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- ratio of 3:1, was not clastogenic in the mouse bone marrow micronucleus test <content styleCode="italics">in vivo</content> and was negative when tested in the <content styleCode="italics">E. coli </content>component of the Ames test <content styleCode="italics">in vitro</content>. <content styleCode="italics">d</content>, <content styleCode="italics">l</content>-Amphetamine (1:1 enantiomer ratio) has been reported to produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the Ames test, and negative responses in the <content styleCode="italics">in vitro</content> sister chromatid exchange and chromosomal aberration assays. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility </content>
                        </paragraph>
                        <paragraph>Amphetamines, in the enantiomer ratio, <content styleCode="italics">d</content>- to <content styleCode="italics">l</content>- ratio of 3:1, did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 6 times the maximum recommended human dose of 25 mg/day given to adolescents on a mg/m<sup>2</sup> body surface area basis).</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a1df8c9a-d395-470f-8b41-693925cd1ded">
                     <id root="f343e1b9-a1be-4463-8be8-a7dc9082c732"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Acute administration of high doses of amphetamine (<content styleCode="italics">d- </content>or <content styleCode="italics">d, l-</content>) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage in rodents. The significance of these findings to humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_05a592ef-2f31-471f-bb5c-1adc6415ed1f">
               <id root="2dda5380-f3fd-4292-be58-8f6083a51567"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Efficacy of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in the treatment of ADHD was established in the following trials: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Three short-term trials in adults (18 to 55 years, Studies 1, 2, and 3) </item>
                     <item>Two short-term trials in pediatric patients (13 to 17 years, Studies 4 and 5) </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Adult Patients (18 to 55 years) with ADHD </content>
                  </paragraph>
                  <paragraph>The approved adult doses, 12.5 mg, 25 mg, and 37.5 mg are based on Studies 1 and 3 and the 50 mg dose efficacy is based on Study 2. Doses up to 75 mg per day (1.5 times the maximum recommended adult dosage) were evaluated, but demonstrated no additional clinical benefit. </paragraph>
                  <paragraph>A 4 week, randomized, double-blind, multicenter, placebo-controlled, forced-dose titration, safety and efficacy study (Study 1) was conducted in adults aged 18 to 55 years (N=275) who met DSM-5 criteria for ADHD. Patients were randomized in a 1:1:1 ratio, to two dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment groups and a placebo group. Group 1 received a dose of 12.5 mg/day throughout the study. Group 2 were titrated on a weekly basis from the initial dose 12.5 mg until target dose of 37.5 mg/day was reached by Week 3 and were maintained at 37.5 mg throughout the study. Group 3 received placebo. </paragraph>
                  <paragraph>The primary efficacy endpoint was defined as the change from baseline of the adult ADHD-Rating Scale (RS) with prompts total score at Week 4. Baseline adult ADHD-RS with prompts total score was defined as the last valid adult ADHD-RS with prompts total score assessment prior to taking the first dose of double-blind investigational product, usually at Visit 2. The primary comparison of interest was at Week 4 for each dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules dose compared with placebo. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules demonstrated a statistically significant treatment effect compared with placebo on change of ADHD-RS total score from baseline at visit 6 (Week 4), for both 12.5 mg and 37.5 mg doses respectively (Study 1 in <content styleCode="italics">Table 4</content>). Patients on dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules also showed statistically significantly greater improvement on the Clinical Global Impression of Improvement (CGI-I) score compared with placebo treatment. </paragraph>
                  <paragraph>Two multicenter, randomized, double-blind, placebo-controlled, crossover studies of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules 25 mg/day (Study 3) and 50 mg/day (Study 2) were conducted in adult patients who met DSM-IV TR criteria for ADHD. The efficacy was determined using the Permanent Product Measure of Performance (PERMP), a skill-adjusted math test that measures attention in ADHD. PERMP total score results from the sum of the number of math problems attempted plus the number of math problems answered correctly. Efficacy assessments were conducted at 2, 4, 8, 12, 14, and 16 hours post-dose using the PERMP. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment, compared to placebo, reached statistical significance at either 2 hours (Study 2) or 4 hours (Study 3) post-dose to 16 hours post-dose in both studies. In a prespecified supplementary analysis for Study 2, the maximum approved dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules (50 mg) demonstrated a statistically significant treatment effect compared with placebo beginning at 2 to 16 hours post-dose (Study 2 and Study 3 in <content styleCode="italics">Table 4</content>). </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pediatric Patients (13 to 17 years) with ADHD</content>
                  </paragraph>
                  <paragraph>A 4 week, randomized, double-blind, multicenter, placebo-controlled, dose-optimization, safety and efficacy study (Study 4) was conducted. In Study 4, the 157 pediatric patients 13 to 17 years old who met DSM-IV TR criteria for ADHD, were randomized in a 1:1 ratio to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules or placebo group. Subjects were titrated from a dose of 12.5 mg/day until an optimal dose was reached (up to a maximum dose of 25 mg); this dose was maintained during the dose-maintenance period (Study 4 in <content styleCode="italics">Table 4</content>). </paragraph>
                  <paragraph>The primary efficacy endpoint was defined as the change from baseline of the ADHD-RS-IV Total Score at Week 4. The baseline ADHD-RS-IV Total Score was defined as the last valid ADHD-RS-IV Total Score assessment prior to taking the first dose of double-blind investigational product, usually at Visit 2. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules demonstrated a statistically significant treatment effect compared with placebo on the change of ADHD RS-IV total scores from baseline at Visit 6 (Week 4). Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules also showed statistically significantly greater improvement on the Clinical Global Impression of Improvement (CGI-I) score at Visit 6 (Week 4). </paragraph>
                  <paragraph>A multicenter, randomized, double-blind, placebo-controlled, crossover study of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules 25 mg/day (Study 5) was conducted in adolescent patients who met DSM-IV TR criteria for ADHD. The efficacy was determined using the Permanent Product Measure of Performance (PERMP), a skill-adjusted math test that measures attention in ADHD. PERMP total score results from the sum of the number of math problems attempted plus the number of math problems answered correctly. Efficacy assessments were conducted at 2, 4, 8, 12, 14, and 16 hours post-dose using the PERMP. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment, compared to placebo, reached statistical significance at 2 to 16 hours post-dose (Study 5 in <content styleCode="italics">Table 4</content>, <content styleCode="italics">Figure 2</content>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: LS Mean (SE) PERMP Total Score by Treatment and Time-Point for Adolescents Ages 13 to 17 with ADHD After 1 Week of Double Blind Treatment (Study 5)</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>In both adults and pediatric patients, examination of a population subset based on gender or race did not reveal any differences.</paragraph>
                  <table width="849px">
                     <caption>Table 4: Summary of Primary Efficacy Results from Short-Term Studies of Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules in Adult and Pediatric Patients with ADHD</caption>
                     <col width="81.9pt"/>
                     <col width="81.9pt"/>
                     <col width="81.9pt"/>
                     <col width="81.9pt"/>
                     <col width="81.9pt"/>
                     <col width="81.9pt"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Study Number (Age range) </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Primary Endpoint </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Treatment Group </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Mean Baseline Score (SD) </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">LS Mean Change from Baseline </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Placebo-subtracted Difference<sup>a</sup>
                                    <br/>
            (95% CI) </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Adult Studies</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 1 </paragraph>
                              <paragraph>(18 to 55 years)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>ADHD-RS </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules (12.5 mg/day)<content styleCode="italics">*</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>39.8 (6.38) </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-18.5 </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-8.1 (-11.7, -4.4) </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules (37.5 mg/day)<content styleCode="italics">*</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>39.9 (7.07) </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-23.8 </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-13.4 (-17.1, -9.7) </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Placebo</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>40.5 (6.52) </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-10.4 </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 2 <br/>
            (18 to 55 years) </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Average PERMP </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <br/>
            (50 mg/day)<content styleCode="italics">*</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>239.2 (75.6)<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>293.23<sup>c</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>18.38 (11.28, 25.47)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Placebo </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>249.6 (76.7)<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>274.85<sup>c</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 3 <br/>
            (18 to 55 years) </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Average PERMP </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <br/>
            (25 mg/day)<content styleCode="italics">*</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>217.5 (59.6)<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>267.96<sup>c</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>19.29 (10.95, 27.63) </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Placebo </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>226.9 (61.7)<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>248.67<sup>c</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" colspan="6" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Pediatric Studies </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 4 </paragraph>
                              <paragraph>(13 to 17 years)<sup>d</sup>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>ADHD-RS-IV </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules (12.5 to 25 mg/day)<content styleCode="italics">*</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>36.7 (6.15) </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-20.3 </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-8.7 (-12.6, -4.8) </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Placebo </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>38.3 (6.67) </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-11.6 </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 5<br/>
            (13 to 17 years) </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Average PERMP </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <br/>
            (25 mg/day)<content styleCode="italics">*</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>214.5 (87.8)<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>272.67<sup>c</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>41.26 (32.24, 50.29) </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Placebo</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>228.7 (101)<sup>b</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>231.41<sup>c</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>SD: standard deviation; LS Mean: least-squares mean; CI: confidence interval.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6"><sup>*</sup>Doses statistically significantly superior to placebo.</td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>a</sup> Difference (drug minus placebo) in least-squares mean change from baseline.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>b</sup> Pre-dose PERMP total score.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>c</sup> LS Mean for PERMP is post-dose average score over all sessions of the treatment day, rather than change from baseline. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>d</sup> Results represent subgroup of Study 4 and not the total population.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c22f1e28-93eb-45ba-ab38-165b6545d595">
               <id root="4b7c135d-cae0-490b-a3cf-7ecacc73f9ef"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">How Supplied</content>
                  </paragraph>
                  <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are available as:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>12.5 mg: Orange opaque cap and body, imprinted with A012 on both cap and body in black ink in the following package size:<br/>
    Bottle of 100 (NDC 0480-3683-01)<br/>
                        <br/>
                     </item>
                     <item>25 mg: Green opaque cap and body, imprinted with A025 on both cap and body in black ink in the following package size:<br/>
    Bottle of 100 (NDC 0480-3684-01)<br/>
                        <br/>
                     </item>
                     <item>37.5 mg: Blue-green opaquecap and body, imprinted with A038 on both cap and body in black ink in the following package size:<br/>
    Bottle of 100 (NDC 0480-3685-01)<br/>
                        <br/>
                     </item>
                     <item>50 mg: Blue opaque cap and body, imprinted with A049 on both cap and body in white ink in the following package size:<br/>
    Bottle of 100 (NDC 0480-3686-01)</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20 to 25C (68 to 77F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container as defined in the USP.</paragraph>
                  <paragraph>Keep this and all medications out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="LINK_75ad8bb0-003f-4a8d-838c-cb6c466d0ab0">
               <id root="dd928c73-6296-4bcf-80a3-3b4b81463f38"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide). </paragraph>
                  <paragraph>
                     <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>Educate patients and their families about the risks of abuse, misuse, and addiction of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, which can lead to overdose and death, and proper disposal of any unused drug <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_803928bf-e36e-434d-a9d8-35220fbb9f45">5.1</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#LINK_a55fd202-f540-43f4-97df-636d83602420">9.2</linkHtml>),</content>
                     <content styleCode="italics">Overdosage (<linkHtml href="#LINK_0a9ef4bb-e365-47e1-aa80-e96f8c16e9d2">10</linkHtml>)]</content>. Advise patients to store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in a safe place, preferably locked, and instruct patients to not give dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules to anyone else.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risks to Patients with Serious Cardiac Disease </content>
                  </paragraph>
                  <paragraph>Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b7cf7dd5-adb8-49df-88fd-cb523373f206">5.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">
                        <content styleCode="underline">Increased</content>Blood Pressure and Heart Rate</content>
                  </paragraph>
                  <paragraph>Instruct patients that dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5ba479ab-d92c-4d44-8118-78a2b172fec7">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Psychiatric <content styleCode="underline">Adverse Reactions</content>
                     </content>
                  </paragraph>
                  <paragraph>Advise patients that dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, at recommended doses, may cause psychotic or manic symptoms even in patients without prior history of psychotic symptoms or mania <content styleCode="italics">[see Warnings and Precautions (5.4)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Long-Term Suppression of Growth<content styleCode="underline">in Pediatric Patients</content>
                     </content>
                  </paragraph>
                  <paragraph>Advise patients, family members, and caregivers that dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may cause slowing of growth including weight loss <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_865384f6-5503-4972-93b6-cad8a5d6f494">5.5</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, Including Raynauds Phenomenon] </content>
                  </paragraph>
                  <paragraph>Instruct patients beginning treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules about the risk of peripheral vasculopathy, including Raynauds phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change from pale, to blue, to red. Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes. Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_06f27598-8645-45aa-94cc-bfcbc6d480cc">5.6</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Seizures </content>
                  </paragraph>
                  <paragraph>Caution patient that dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may lower the convulsive threshold. Advise patients to contact their healthcare provider immediately and to discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules if a seizure occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_5e775066-0803-45e6-b561-43817bd1e23f">5.7</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome </content>
                  </paragraph>
                  <paragraph>Caution patients about the risk of serotonin syndrome with concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. Johns Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_be8d1088-0eff-4882-9919-b51eeecf1c65">4</linkHtml>), Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_1c0b3f71-d71e-4272-b561-0bd73a8c61f2">5.8</linkHtml>), Drug Interactions (<linkHtml href="#www.splportal.comLINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)].</content> Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Motor and Verbal Tics, and Worsening of Tourettes Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that motor and verbal tics and worsening of Tourettes syndrome may occur during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourettes syndrome occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_f20d4ce6-ae6f-4d37-88d8-071aeecb2086">5.10</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Concomitant Medications </content>
                  </paragraph>
                  <paragraph>Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs because there is a potential for interactions <content styleCode="italics">[see Drug Interactions (<linkHtml href="#LINK_0ec88a24-39d7-48a1-b129-0c8890ab275e">7.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy Registry</content>
                     <br/>
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules during pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#LINK_9361a3c9-46cd-4baf-82d3-79bf4953f6ca">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy </content>
                  </paragraph>
                  <paragraph>Advise patients of the potential fetal effects from the use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules during pregnancy. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9361a3c9-46cd-4baf-82d3-79bf4953f6ca">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation </content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed if they are taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_6196e00d-1643-48e9-935e-498cfd4c5fc2">8.2</linkHtml>)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Alcohol </content>
                  </paragraph>
                  <paragraph>Advise patients to avoid alcohol while taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Consumption of alcohol while taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may result in a more rapid release of the dose of mixed amphetamine salts <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_c9f1b510-e5d9-44fa-b30c-38c61dc4a54b">12.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>For more information call Teva at 1-888-838-2872.</paragraph>
                  <paragraph>Dispense with Medication Guide available at: www.tevausa.com/medguides</paragraph>
                  <paragraph>Manufactured For:<br/>
                     <content styleCode="bold">Teva Pharmaceuticals<br/>
                     </content>Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. B 12/2024</paragraph>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3d90d9b8-238a-43de-bfa4-439f79ca5588">
               <id root="9669619c-2071-4e03-a5f6-a20d9aa21c2b"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>MEDICATION GUIDE</title>
               <text>
                  <table width="1000px" cellpadding="5">
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="5">
                              <paragraph>Dispense with Medication Guide available at: www.tevausa.com/medguides</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="5" styleCode=" Botrule Toprule Lrule Rrule"><content styleCode="bold">Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate,<br/>
            Dextroamphetamine Sulfate, and Amphetamine Sulfate<br/>
            (dex</content>
                              <content styleCode="bold">" troe am fet</content>
                              <content styleCode="bold">' a meen sak a rate, am fet</content>
                              <content styleCode="bold">' a meen a spar</content>
                              <content styleCode="bold">' tate,<br/>
            dex</content>
                              <content styleCode="bold">" troe am fet</content>
                              <content styleCode="bold">' a meen sul</content>
                              <content styleCode="bold">' fate, and am fet</content>
                              <content styleCode="bold">' a meen sul</content>
                              <content styleCode="bold">' fate)<br/>
            Extended-Release Capsules, CII<br/>
            (Mixed-Salts of a Single-Entity Amphetamine Product)</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
            <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules can cause serious side effects, including: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Abuse, misuse, and addiction.</content> Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, other amphetamine containing medicines, and methylphenidate containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules or when it is used in ways that are not approved, such as snorting or injection.
                <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should check you or your childs risk for abuse, misuse, and addiction before starting treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and will monitor you or your child during treatment.</item>
                                       <item>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                       <item>Do not give dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules to anyone else. See <content styleCode="bold">What are dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules</content>? for more information.</item>
                                       <item>Keep dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in a safe place and properly dispose of any unused medicine. See <content styleCode="bold">How should I store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules</content>? for more information.</item>
                                    </list>
                                    <paragraph>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines or street drugs.</paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Risks for people with serious heart disease. </content>Sudden death has happened in people who have heart defects or other serious heart disease.
                <paragraph>Your healthcare provider should check you or your child carefully for heart problems before starting dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Tell your healthcare provider if you or your child have any heart problems, heart disease, heart defects.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.</content>
                                    </paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate.<br/>
                                    </content>Your healthcare provider should check you or your childs blood pressure and heart rate regularly during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Mental (psychiatric) problems, including: </content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>new or worse behavior and thought problems </item>
                                       <item>new or worse bipolar illness </item>
                                       <item>new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph> Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems while taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules? </content>
                              </paragraph>
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 13 years of age and older. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are not for use in children 12 years of age and younger. </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are a federally controlled substance (CII) because it contains amphetamine that can be a target for people who abuse prescription medicines or street drugs. </content>Keep dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in a safe place to protect it from theft. Never give your dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules to anyone else, because it may cause death or harm them. Selling or giving away dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may harm others and is against the law.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Do not take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules if you or your child are: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>allergic to amphetamine or any of the ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. See the end of the Medication Guide for a complete list of ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. </item>
                                 <item>taking, or have taken within the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI).</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, tell your healthcare provider about all medical conditions, including if you or your child: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>have heart problems, heart disease,heart defects or high blood pressure </item>
                                 <item>have mental problems including psychosis, mania, bipolar illness or depression, or have a family history of suicide, bipolar illness, or depression</item>
                                 <item>have circulation problems in fingers and toes </item>
                                 <item>have or have had seizures </item>
                                 <item>have kidney problems</item>
                                 <item>have or had repeated movements or sounds (tics) or Tourettes syndrome, or have a family history of tics or Tourettes syndrome </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.
                <list listType="unordered" styleCode="Circle">
                                       <item>There is a pregnancy registry for females who are exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules during pregnancy. The purpose of the registry is to collect information about the health of females exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and their baby. If you or your child becomes pregnant during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visit online at https://womensmentalhealth.org/research/pregnancyregistry/.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate passes into breast milk. You should not breastfeed during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines that you or your child take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may affect the way other medicines work and other medicines may affect how dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules work. Taking dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules with other medicines can cause serious side effects. </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you or your child take:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>selective serotonin reuptake inhibitors (SSRIs)</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>serotonin norepinephrine reuptake inhibitors (SNRIs)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>medicines used to treat migraine headaches called triptans</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>tricyclic antidepressants</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>lithium</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>fentanyl</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>tramadol</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>tryptophan</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>buspirone</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>St. Johns Wort</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Lrule Rrule">Know the medicines that you or your child take. Keep a list of your medicines with you to show your or your childs healthcare provider and pharmacist when you or your child get a new medicine.
            <paragraph>Your healthcare provider will decide whether dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules can be taken with other medicines.<content styleCode="bold">Do not start any new medicine during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules without talking to your or your childs healthcare provider first.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules? </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules exactly as prescribed by your healthcare provider. </item>
                                 <item>Your healthcare provider may change the dose if needed. </item>
                                 <item>Take dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules 1 time each day in the morning right after you wake-up. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may last up to 16 hours and can cause difficulty sleeping. </item>
                                 <item>If you miss a dose of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, <content styleCode="bold">do not</content> take your dose later in the day or double your dose to make up for a missed dose. Take your dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules dose the next morning at your regularly scheduled time. </item>
                                 <item>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules can be taken with or without food but take it the same way each time. </item>
                                 <item>Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may be swallowed whole <content styleCode="bold">or</content> if dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules cannot be swallowed whole, the capsules may be opened and sprinkled over a spoonful of applesauce.
                <list listType="unordered" styleCode="Circle">
                                       <item>swallow all of the applesauce and medicine mixture right away </item>
                                       <item>
                                          <content styleCode="bold">do not</content> chew the applesauce and medicine mixture </item>
                                       <item>
                                          <content styleCode="bold">do not</content> store the sprinkled applesauce </item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>If you or your child takes too many dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules, call your healthcare provider or Poison Help line at 1-800-222-1222or go to the nearest hospital emergency room right away.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules? </content>
                              </paragraph>
                              <paragraph>You should avoid drinking alcohol during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are possible side effects of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules may cause serious side effects, including: </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>See <content styleCode="bold">What is the most important information I should know about dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules?</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Slowing of growth (height and weight) in children.</content> Children should have their height and weight checked often during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. Your healthcare provider may stop your childs dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules treatment if they are not growing or gaining weight as expected. </item>
                                 <item>
                                    <content styleCode="bold">Circulation problems in fingers and toes (peripheral vasculopathy, including Raynauds phenomenon). Signs and symptoms may include: </content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>fingers or toes may feel numb, cool, painful </item>
                                       <item>fingers or toes may change color from pale, to blue, to red </item>
                                    </list>
                                    <paragraph>Tell your healthcare provider if you have or your child has any numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes. </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Call your healthcare provider if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. </content>
                                    </paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Seizures.</content> Your healthcare provider will stop treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules if you have a seizure.</item>
                                 <item>
                                    <content styleCode="bold">New or worsening tics or worsening Tourettes Syndrome. </content>Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourettes syndrome during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. </item>
                                 <item>
                                    <content styleCode="bold">Serotonin syndrome.</content> This problem may happen when dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules are taken with certain other medicines and may be life-threatening. Call your healthcare provider or go to the nearest hospital emergency room if you get symptoms of serotonin syndrome which may include: </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule">
            <list listType="unordered" styleCode="Circle">
                                 <item>agitation, hallucinations, coma</item>
                                 <item>loss of coordination</item>
                                 <item>flushing</item>
                                 <item>fast heartbeat</item>
                                 <item>seizures</item>
                                 <item>confusion</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode=" Rrule">
            <list listType="unordered" styleCode="Circle">
                                 <item>sweating or fever</item>
                                 <item>nausea, vomiting, or diarrhea</item>
                                 <item>dizziness</item>
                                 <item>changes in blood pressure</item>
                                 <item>muscle stiffness or tightness</item>
                                 <item>high body temperature (hyperthermia)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Lrule Rrule">
                              <content styleCode="bold">The most common side effects of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules include:</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>trouble sleeping</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disk">
                                 <item>increased heart rate</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>irritability</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule">
            <list listType="unordered" styleCode="Disc">
                                 <item>decreased appetite </item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disk">
                                 <item>anxiety</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>weight loss</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>dry mouth</item>
                              </list>
                           </td>
                           <td>
                              <list listType="unordered" styleCode="Disk">
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule"></td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Lrule Rrule">
                              <paragraph>These are not all the possible side effects of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules. </paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules? </content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules at room temperature between 68F to 77F (20C to 25C). </item>
                                 <item>Protect dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules from light. </item>
                                 <item>Store dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in a safe place, like a locked cabinet. </item>
                                 <item>Dispose of remaining, unused, or expired dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines. </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules </content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules for a condition for which it was not prescribed. Do not give dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules to other people, even if they have the same condition. It may harm them and it is against the law. You can ask your healthcare provider or pharmacist for information about dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules that is written for healthcare professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release capsules?<br/>
                                 </content>
                                 <content styleCode="bold">Active ingredients:</content> dextroamphetamine sulfate and amphetamine sulfate, dextroamphetamine saccharate and amphetamine aspartate monohydrate<br/>
                                 <content styleCode="bold">Inactive ingredients:</content> ethylcellulose, hypromellose 2910, iron oxide red, iron oxide yellow, methacrylic acid copolymer dispersion; methyl acrylate, methyl methacrylate, and methacrylic acid copolymer; polyethylene glycol 400, polysorbate 80, sugar spheres (which contains corn starch and sucrose), talc, titanium dioxide, and triethyl citrate. The capsule shells contain gelatin, sodium lauryl sulfate, titanium dioxide. In addition, the 12.5 mg capsule shell contains carboxymethylcellulose, iron oxide red, and iron oxide yellow; the 25 mg capsule shell contains carboxymethylcellulose, FD&amp;C Blue #1, iron oxide red, and iron oxide yellow; the 37.5 mg capsule shell contains carboxymethylcellulose, FD&amp;C Blue #1 and FD&amp;C Red #40, and iron oxide red; 50 mg capsule shell contains FD&amp;C Blue #1 and FD&amp;C Red #40. The printing ink for 12.5 mg, 25 mg, and 37.5 mg capsule contains ammonium hydroxide, iron oxide black, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution. The printing ink for the 50 mg capsule contains ammonium hydroxide, povidone, propylene glycol, simethicone (which contains dimethicone and silicon dioxide), shellac, sodium hydroxide, and titanium dioxide.</paragraph>
                              <paragraph>Manufactured For:<content styleCode="bold"> Teva Pharmaceuticals,</content> Parsippany, NJ 07054<br/>
            For more information call Teva at 1-888-838-2872.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration                                               Rev. B 12/2024</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c96b7e55-2c2d-4187-b787-047c040372ba">
               <id root="0766393a-ceca-4b26-8503-acf825295721"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel</title>
               <text>
                  <paragraph>NDC0480-3683-01</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>Dextroamphetamine Saccharate,Amphetamine AspartateMonohydrate, DextroamphetamineSulfate, and Amphetamine Sulfate(Mixed Salts of a Single-Entity Amphetamine Product) Extended-Release Capsules</paragraph>
                  <paragraph>12.5 mg</paragraph>
                  <paragraph>ONCE-DAILY</paragraph>
                  <paragraph>Do not substitute for Adderall XR<sup></sup>.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_19f0f2c5-8dc1-4fde-b2e9-d7afbe85c253">
               <id root="01a17b58-9998-4d38-b026-7c635262fb01"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel</title>
               <text>
                  <paragraph>NDC0480-3684-01</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>Dextroamphetamine Saccharate,Amphetamine AspartateMonohydrate, DextroamphetamineSulfate, and Amphetamine Sulfate(Mixed Salts of a Single-Entity Amphetamine Product) Extended-Release Capsules</paragraph>
                  <paragraph>25 mg</paragraph>
                  <paragraph>ONCE-DAILY</paragraph>
                  <paragraph>Do not substitute for Adderall XR<sup></sup>.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5bfa068a-d464-42d9-9d15-0b2e48a3c011">
               <id root="2ba19a0a-f4ff-4f09-9bd6-f4af7767baa9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel</title>
               <text>
                  <paragraph>NDC0480-3685-01</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>Dextroamphetamine Saccharate,Amphetamine AspartateMonohydrate, DextroamphetamineSulfate, and Amphetamine Sulfate(Mixed Salts of a Single-Entity Amphetamine Product) Extended-Release Capsules</paragraph>
                  <paragraph>37.5 mg</paragraph>
                  <paragraph>ONCE-DAILY</paragraph>
                  <paragraph>Do not substitute for Adderall XR<sup></sup>.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_81310a28-c5e0-4e8c-8e85-0296b1bcd326">
               <id root="92735938-47eb-4e8c-ac69-49def74b633b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel</title>
               <text>
                  <paragraph>NDC0480-3686-01</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>Dextroamphetamine Saccharate,Amphetamine AspartateMonohydrate, DextroamphetamineSulfate, and Amphetamine Sulfate(Mixed Salts of a Single-Entity Amphetamine Product) Extended-Release Capsules</paragraph>
                  <paragraph>50 mg</paragraph>
                  <paragraph>ONCE-DAILY</paragraph>
                  <paragraph>Do not substitute for Adderall XR<sup></sup>.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>